InvestSMART

ImExHS Limited (ASX:IME)

ALERT: Price-sensitive ASX Announcement for IME
Current share price for IME : $0.310 -0.035 (-10.14%)+
Announcement
Release
31 Jul 2026 10:59AM
Price at Release
$0.345
Full Release
download
Summary
In the quarterly report for Q2 FY26, ImExHS Limited reported a net cash inflow of $0.1 million from operating activities, with cash receipts totaling $6.5 million, indicating improvement over the previous quarter. Investment in capitalized software was $0.2 million, while financing activities consumed $0.4 million, leading to a reduction in debt to $0.25 million by the end of June 2026. The company anticipates surpassing FY25's Underlying EBITDA, achieving a cash-positive position for FY26, and accelerating software revenue growth. Key achievements include a significant public tender win in Mexico to deploy the Aquila+ platform across multiple hospitals, enhancing the company's ARR and reaffirming its strategic international expansion, particularly in AI-integrated radiology solutions. The software ARR stood at $11.75 million by mid-year, with efforts focused on leveraging the Aquila+ platform for all new contracts.
Key Points
  • Net cash received in operating activities was $0.1 million for the quarter.
  • Cash receipts amounted to $6.5 million, higher than the previous quarter.
  • Investing activities consumed $0.2 million, with $0.2 million allocated to capitalized software.
  • Financing activities used $0.4 million, reducing debt to $0.25 million as of June 30, 2026.
  • The company expects to exceed FY25 Underlying EBITDA and be cash positive for FY26.
  • Software revenue growth is anticipated to outpace the previous fiscal year.
  • Major contract secured with a public tender in Mexico, contributing significantly to ARR.
  • The Aquila+ platform is crucial for new contracts and software deployments.
  • Company's software ARR at $11.75 million by June 2026.
  • Focus is on AI-integrated radiology deployments and expansion in international markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.